By Chris Wack
Recursion Pharmaceuticals shares were down 7% to $7.12 after the company reported a fourth-quarter loss that was wider than analysts expected.
The clinical-stage biotechnology company said it had a quarterly loss of $178.9 million, or 53 cents a share, compared with a loss of $93 million, or 42 cents a share, in the same quarter a year prior. Analysts polled by FactSet were looking for a loss of $124.8 million, or 41 cents a share.
Revenue for the quarter was $4.55 million, compared with last year's $10.9 million and the $15.3 million analysts were expecting.
The company said that for the fourth quarter, the decrease of revenue compared to the prior period was due to the timing of projects from its collaboration with Roche and Genentech.
Recursion had a cash position of $603 million as of Dec. 31, compared with $401.4 million as of Dec. 31, 2023. On a combined basis, Recursion expects its cash runway to extend into 2027.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
February 28, 2025 10:09 ET (15:09 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。